Flagship Ventures 2007 General Partner’s Cartesian Therapeutics RNAC Stock Holding History

Flagship Ventures 2007 General Partner’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	$23.1M	Buy	+55,062	New	+$23.1M	21.5%	2

Other funds holding RNAC

PVMCV

Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Flagship Ventures 2007 General Partner's RNAC Position: Q2 2016 in Review

Flagship Ventures 2007 General Partner opened a new position in Cartesian Therapeutics (RNAC) in Q2 2016: 55,062 shares worth $23.1M. The stake represents 21.5% of the portfolio and ranks #2 among its holdings.

16 funds tracked by Wall St. Rank hold RNAC as of Q2 2016.

Flagship Ventures 2007 General Partner held 55,062 shares of Cartesian Therapeutics worth $23.1M as of Q2 2016.
Cartesian Therapeutics was a new Flagship Ventures 2007 General Partner position in Q2 2016.
Cartesian Therapeutics made up 21.5% of Flagship Ventures 2007 General Partner's portfolio in Q2 2016, its #2 holding.
16 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2016.

Based on Flagship Ventures 2007 General Partner's 13F filing for Q2 2016, filed 15 Aug 2016.